Table 5.

Participants with end-of-treatment failure and breakthrough (consensus Sanger sequence)

Participant code	Treatment arm	HCV genotype	RASs
			Baseline	At the time of failure
End-of-treatment failure
38-U	25 mg/PEG-IFN/RBV	1a	WT	A156L
38-V	25 mg/PEG-IFN/RBV	1a	WT	WT
Breakthrough
38-W	100 mg/PEG-IFN/RBV	1b	Y56F, V170I	(Y56F), R155W, A156G, D168N
39-F	100 mg/RBV	1a	WT	A156T, D168N
39-G	100 mg/RBV	1a	WT	Y56H, D168A
39-H	100 mg/RBV	1b	WT	Y56H, D168A

Note: RASs with grazoprevir resistance are shown in bold.

Abbreviations: HCV, hepatitis C virus; PEG-IFN/RBV, peginterferon/ribavirin; RAS, resistance-associated substitution; RBV, ribavirin; WT, wild-type.